Long QT Syndrome
Clinical Presentation
1.
Palpitations
2.
Pre-syncope or syncopeš
often due to torsades de pointes
3.
Cardiac arrest and deathš
secondary to ventricular fibrillation
Differential Diagnosis
1.
Vasovagal syncope
2.
Hypertrophic Cardiomyopathy
3.
Brugada syndrome
4.
Catecholaminergic polymorphic ventricular tachycardia
5.
Hypocalcemia
6.
Hypothyroidism
7.
Medications that prolong QT
Labs/Test
1.
Normal physical exam
2.
Detailed family history
3.
EKG: abnormal, prolonged QT interval
4.
ECHOš normal
(only helps to R/O other causes)
5.
Cardiac MRIš normal
6.
Epinephrine challengeš
specific to LQT1 mutation
7.
Genetic testingš
negative test doesnÕt R/O diagnosis, but positive test can provide prognosis
and guide therapeutics, also can help R/O diagnosis in other family members
Pathophysiology
1.
Congenital or acquired
2.
Ten genes linked to congenital LQTS, but three genes that encode a cardiac ion
channel responsible for ventricular repolarization
account for majority of cases (LQT1, LQT2, LQT3)
a. LQT1: most common, triggered by
emotional or physical stress (specifically diving and swimming), associated
with autosomal recessive Jerrvell
and Lange-Nielseen Syndrome (LQTS with congenital sensorneural hearing loss)
b. LQTS2: syncope or sudden death with
stress or at rest, events triggered by sudden loud noises (almost diagnostic),
normal hearing
c. LQTS3: associataed
with bradycardia, may be casue of syncope.
3. Two
clinical phenotypes described in congenital LQTS, based on type of inheritance
and resence or absence of sensoineural
hearing loss
a. Romano-Ward Syndrome
i More common form
ii Autosomal dominant
iii Purely cardiac phenotype
b. Jervel and
Lange-Nielsen Syndrome
i Autosomal
recessive
ii Only been describe in LQTS1 abd
LQTS5
iii Associated with LQTS and sensorineural
deafness
iv More malignant clinical course
4.
Acquired LQTS usually results from drugs that prolong the QT interval,
electrolyte disturbances, or metabolic abnormalities.
Risk Stratification
1.
Length of QTc at resentation
is a predictor of sudden cardiac death.
Treatment
1.
Beta-blockers
a.
Long acting: nadolol and atenolol
2.
Implantable cardioverter-defibrillators (ICDs)
a.
Considered for patients with high risk for cardiac death
2.
Left cardiac sympathetic denervation (i.e. left stellate cardiac ganglionectomy)
1.
Main indications are failure of medical therapy, frequent shocks with an IC
despite medicataions.
2.
Cardiac pacing
1.
Used in patients with congenital LQTS who remain symptomatic despite beta
blockers, particularly thosie in whom bradycardia facilitates torsades
de pointes (paatients with LQTS3, which is associated
with bradycardia)
2.
For acquired forms of LQTS; discontinuation of
offending drug, correct underlying metabolic or electrolyte disurbance.
References
1.
Roden, D. Long QT Syndrome. NEJM 2008;358:169-76.
2.
Chiang,CE, Roden, DM The long QT syndrome: genetic basis and clinical
implications. J AM Coll Cardiol
2000;36 1-12
3.
Haverkamp,W et al. The
potential for QT prolongations and proarrhythmia by
non-antiarrhythmic drugs: clinical and regulatory
implications. Report on a policy conference of the European Society of
Cardiology. Eur Heart J 2000;21
1216-1231
4.
Schwartz,PJ et al. Left
cardiac sympathitic denervation
in the management of high-risk patients affected by the long QT syndrome.
Circulaation 2004;109;1826-1833
5.
Viskin,S Cardiac pacing in
the long QT syndrome: review of available data and practical recommendations. J
Cardiovasc Electrophysiol
2000;11:593-600
6.
Zipes,DP et al. ACC/AHA/ESC 2006 Guideline for
Management of Patient with Ventricular Arryhthmias
and the Prevention of Sudden Cardiac Death. J Am Coll Cardiology 2006;48:1064-1108